目前全球有4款获批治疗乳腺癌的细胞周期蛋白依赖性激酶（CDK）4/6抑制剂，分别是哌柏西利、瑞博西利、阿贝西利和达尔西利。其中，阿贝西利是继哌柏西利和瑞博西利之后第3个进入市场的CDK4/6抑制剂，可联合芳香化酶抑制剂（AI）或他莫昔芬作为激素受体阳性（HR⁺）、人表皮生长因子受体2阴性（HER2^-）早期高危乳腺癌成人患者的辅助治疗，还可联合氟维司群或AI治疗HR⁺/HER2^-局部晚期或转移性乳腺癌。就阿贝西利治疗激素受体阳性乳腺癌的临床研究进展作以综述，以期为临床治疗提供参考。

At present, there are four cyclin-dependent kinase 4/6 inhibitors approved for the treatment of breast cancer in the world, namely:Palbociclib, Ribociclib, Aabemaciclib and Dalpiciclib. Abemaciclib is the third CDK4/6 inhibitor to enter the market after Palbociclib and Ribociclib. It can be combined with aromatase inhibitors or tamoxifen as adjuvant therapy for adult patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR⁺/HER2^-) early high-risk breast cancer, and can also be combined with fulvestrant or AI in the treatment of HR⁺/HER2^- locally advanced or metastatic breast cancer. This article reviews the clinical research progress of abemaciclib in the treatment of hormone receptor positive breast cancer, in order to provide reference for clinical treatment.

R979.1

国家自然科学基金资助项目（82104553）